Market research
PJ2N.F Liminal BioSciences Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 30.61
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- CA53272L1031
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 30.61
About
About Liminal BioSciences Inc
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PJ2N.F discussion.
5 years, 4 months ago
Liminal BioSciences Inc is currently in a long term downtrend where the price is trading 25.1% below its 200 day moving average.
From a valuation standpoint, the stock is 97.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 38.3.
Liminal BioSciences Inc's total revenue rose by 106.0% to $1M since the same quarter in the previous year.
Its net income has dropped by 176.7% to $-40M since the same quarter in the previous year.
Finally, its free cash flow fell by 14.5% to $-27M since the same quarter in the previous year.
Based on the above factors, Liminal BioSciences Inc gets an overall score of 2/5.